Your Questions Answered! CREST Syndrome
Originally
published in "Scleroderma Voice," 2004 #4
QUESTION:
I was recently diagnosed with CREST Syndrome and am
receiving some conflicting information about this disease.
Is CREST Syndrome the same as scleroderma?
ANSWER:
CREST Syndrome, as it was known for many years, is
one of three forms of systemic scleroderma: diffuse
cutaneous systemic sclerosis, limited cutaneous systemic
sclerosis, and a rare form of the disease known as systemic
sclerosis sine scleroderma. Each will be defined in
turn. CREST is an acronym that was created to describe
the hallmarks of the disease by its most visible features.
The letters represent the following: C-calcinosis, R-raynauds,
E-esophageal dysfunction, S-sclerodactyly and T-telangectasias.
In more recent years, as understanding of scleroderma
has increased, it became apparent there was more to
CREST Syndrome than the mere external manifestations
of the disease. For this reason, the rheumatology community
has increasingly moved away from this acronym in favor
of the term “limited cutaneous systemic sclerosis”
or just “limited scleroderma.” However,
some physicians still use the term CREST Syndrome, as
it can be easier for a patient to understand.
The terms limited, diffuse, and sine are diagnoses
that are based on the extent of skin involvement seen
on examination, but one is not considered more or less
serious than the other. Persons with limited scleroderma
generally have skin involvement that does not extend
above the elbow or above the knee, although in some
patients, the face can be affected. Those with diffuse
scleroderma can have widespread skin thickening involving
the entire body, and individuals with sine scleroderma
will have nonexistent or extremely minor skin involvement.
Sine scleroderma has all the internal organ manifestations
of the disease, and this is generally the basis on which
the diagnosis is made.
Always remember that this disease is highly individualized.
Not every person who is diagnosed with systemic scleroderma
will have the same presentation. Some may have a mild
form of the disease while others may have more progressive
disease. It is also important to understand that scleroderma
is a life-long, chronic condition. There is no known
cure, but there are therapies to address the symptoms
of this disease. Natural progression of the disease
is such that the first few years can be rocky with the
onset of symptoms. Over time, progression of the disease
will quiet down and some people will enjoy periods of
remission.
There
are several very important things that you and your
physician can do to effectively manage your scleroderma.
The most critical is early detection of problems to
minimize or prevent complications. This is accomplished
through a series of tests that are performed at the
time of diagnosis to provide a baseline, and then conducted
on a regular basis thereafter. It is imperative that
every single person diagnosed with systemic scleroderma,
whether limited or diffuse, has these done. These screenings
can alert your physician to potential problem areas
even before you become symptomatic. Early detection
can make a difference in treatment options, and more
importantly, on treatment outcomes.
| Diagnostics
required to monitor your lung function are:
– Pulmonary function tests (PFTs) at baseline
and serially at six months to one year intervals
– Echocardiogram at baseline and then annually
– Chest x-ray at baseline and then annually
– High-resolution computed tomography (CTScan)
of the lungs may also be conducted |
Pulmonary arterial hypertension may occur in 25–50%
of persons with limited scleroderma. Interstitial lung
disease may occur in 10% of this population.
Renal involvement is less commonly associated with
limited scleroderma, but is still a consideration. Patients
should monitor their blood pressure several times per
week to be alerted to any increases, as new onset hypertension
can precipitate renal crisis.
Persons with the limited form of the disease generally
have difficulty with their gastrointestinal tract. For
a clear understanding of these complications, treatments
and diagnostics, please refer to the following article:
Medical
Report: Digestive System (Gut, Gastro-intestinal) Involvement
in Scleroderma.
One should also take great care to manage their Raynaud’s
phenomenon. Minimizing attacks through practical lifestyle
changes and protective measures can reduce the amount
of damage from these vasospasms. If you would like more
detailed information about this topic, we have several
comprehensive articles that may be helpful. They are
available on our website, www.scleroderma.org/medical/raynauds.shtm,
or by calling our toll-free HelpLine at 800-722-HOPE
(4673).
Equally
important is scheduling regular visits with your rheumatologist.
Your rheumatologist will be the quarterback of your
health care team. He or she should coordinate the bulk
of your care and monitor your serial diagnostics, referring
you to other specialists as indicated. It is not unusual
for some patients to consult with a pulmonologist, gastroenterologist,
cardiologist, or nephrologist at various times in order
to access the most appropriate treatment. Although juggling
all these visits may seem overwhelming, doing things
such as obtaining copies of your test results, keeping
a record of your medications, and tracking the dates
of your last office visits can help you to feel more
in control of the situation. It is also important to
make sure that each of these specialists communicates
your test results and any medication changes or additions
to your rheumatologist, so he or she has complete records.
It is also a good idea to work with a physician with
whom you can have an open and honest dialogue about
new or changing symptoms, and who is willing to address
any other reasonable concerns you may have.
|